Imiquimod in the treatment of lentigo maligna

British Journal of Dermatology

Volumn 155, Issue 4, 2006, Pages 653-656

  Rajpar, S F ^a   Marsden, J R ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Imiquimod; In situ melanoma; Lentigo maligna; Radiotherapy; Review; Surgery

Indexed keywords

IMIQUIMOD;

DRUG RESPONSE; DRUG TOLERANCE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT LENTIGO; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; INTERFERON INDUCERS; SKIN NEOPLASMS;

EID: 33748454894     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07476.x     Document Type: Review

References (33)

1. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116:303-10.
2. Osborne JE, Hutchinson PE. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg 2002; 55:611-15.
3. Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol 2004; 140:552-8.
4. Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg 1998; 24:673-7.
5. Agarwal-Antal N, Blowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002; 47:743-8.
6. Wayte DM, Helwig EB. Melanotic freckle of Hutchinson. Cancer 1968; 21:893-911.
7. Elder D, Elenitsas R, Jaworsky C, Johnson B Jr. Lever's Histopathology of the Skin, 8th edn. Philadelphia, PA: Lippincott-Raven, 1997.
8. Mahendran RM, Newton-Bishop JA. Survey of U.K. current practice in the treatment of lentigo maligna. Br J Dermatol 2001; 144:71-6.
9. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143:843-5.
10. Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 2003; 139:943-4.
11. Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 2003; 139:944-5.
12. Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol 2003; 139:945-7.
13. Naylor MF, Crowson N, Kuwahara R et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 (Suppl. 66):66-70.
14. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004; 29:15-21.
15. Powell AM, Russell-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol 2004; 50:792-6.
16. Kupfer-Bessaguet I, Guillet G, Misery L et al. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation. J Am Acad Dermatol 2004; 51:635-9.
17. Fleming CJ, Bryden AM, Evans A et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004; 151:485-8.
18. Michalopoulos P, Yawalkar N, Brönnimann M et al. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol 2004; 151:903-6.
19. Munoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg 2004; 30:1543-5.
20. Kamin A, Eigentler TK, Radny P et al. Imiquimod in the treatment of extensive recurrent lentigo maligna. J Am Acad Dermatol 2005; 52(2 Suppl. 1):51-2.
21. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005; 141:510-14.
22. Noel B, Kunzle N. Lentigo maligna. N Engl J Med 2005; 353:2176.
23. Ray CM, Kluk M, Grin CM et al. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 2005; 44:428-34.
24. Wolf IH, Smolle J, Binder B et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003; 139:273-6.
25. Davis J, Pack GT, Higgins GK. Melanotic freckle of Hutchinson. Am J Surg 1967; 113:457-63.
26. Gupta AK, Cherma AM, Tying SK. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg 2004; 8:338-52.
27. Panizzon RG. Radiotherapy of lentigo maligna and lentigo maligna melanoma. Skin Cancer 1999; 14:203-7.
28. Arma-Szlachcic M, Ott F, Storck H. [The X-ray treatment of melanotic precancerosis. Study of 88 follow-up cases]. Hautarzt 1970; 21:505-8.
29. Schmid-Wendtner MH, Brunner B, Konz B et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43:477-82.
30. Tsang RW, Liu FF, Wells W, Payne DG. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994; 130:1008-12.
31. Christie DR, Tiver KW. Radiotherapy for melanotic freckles. Australas Radiol 1996; 40:331-3.
32. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146:1042-6.
33. Ballo M, Ang K. Radiation therapy for malignant melanoma. Surg Clin North Am 2003; 83:323-42.